We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Smith & Nephew Plc | LSE:SN. | London | Ordinary Share | GB0009223206 | ORD USD0.20 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
2.00 | 0.20% | 985.40 | 985.00 | 985.40 | 987.40 | 974.00 | 982.60 | 411,567 | 11:34:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Ortho,prosth,surg Appl,suply | 5.55B | 263M | 0.3011 | 32.75 | 8.61B |
Date | Subject | Author | Discuss |
---|---|---|---|
14/9/2021 11:52 | OK Covid protective measures winding down but infections up though looking as though starting to go down but deaths starting to increase -However with restrictions coming off and winter coming very likley (imo)to be an acceration to the upside of both cases hospitalisations and deaths and therefore a decline in elective surgery BAD for SN. Use above link if you wish to double check trends - | pugugly | |
14/9/2021 10:28 | A little good news here would be more than welcome given the positive interims. Surely the Company has a fair indication of upswing now as Covid measures wind down. I think it would be prudent to issue an interim t/u in view of the continued share price erosion if only to stop the rot. | luzley | |
10/9/2021 11:26 | I'll take £18 now please. Suet | suetballs | |
10/9/2021 11:02 | BARCLAYS CUTS SMITH & NEPHEW PRICE TARGET TO 1,800 (1,825) PENCE - 'OVERWEIGHT' | philanderer | |
24/8/2021 19:32 | SP has bounced several times from the approx 13.75 type area. Some type of support around there?, not holding atm. | essentialinvestor | |
24/8/2021 18:58 | Today's RNS details shares issued partly in lieu of annual fees. If you read yesterday's RNS, it's yet another director sale. | essentialinvestor | |
24/8/2021 18:47 | What's going on with this share director buys big price goes down. | csalvage | |
16/8/2021 09:24 | I expect we will get increasingly positive updates going forward as pent-up demand escalates and facilities reopen to clear backlogs. American healthcare consumers are not the most patient in the world. | luzley | |
16/8/2021 09:23 | Affluent areas of US are facing much better - that's where most joint surgery is focused. | luzley | |
16/8/2021 08:25 | Ok so no quick profits - but long term I am optimistic. Suet | suetballs | |
16/8/2021 08:16 | Thing is most of their business is in the us where things are getting worse | spoole5 | |
13/8/2021 22:19 | Looking to invest here, this seems like a great company with bags of potential for a Covid recovery play. Watching closely. | chard1980 | |
12/8/2021 14:49 | H2 guidance is predicated on normalisation of the COVID pandemic in their major markets. Now currently we have the COVID situation in the US rapidly deteriorating- hopefully that may peak within the next few weeks. May be that is discounted at the current share price level, or someone else will see longer term value and make an offer for the Company. Ian, interesting re the epidural, these days they are far more cautious using GA. Back in the day you were often put under general for even minor surgery. | essentialinvestor | |
12/8/2021 14:39 | Keyno, you’re right. I got fed up waiting for someone to make some enlightened comment that would put some life into this board, hopefully I’ve done that. Now make some comment on what I said about +37% to +49% that’s constructive ! | basildublin | |
12/8/2021 13:23 | Basil has only been on ADVFN since yesterday. | keyno | |
12/8/2021 11:49 | Bought a few today. Gotta b cheap. | its the oxman | |
12/8/2021 10:49 | Ian, when S&N say the numbers are the correct interpretation of the guidance it gives a certain validity to the figures. | basildublin | |
12/8/2021 10:49 | Ian, when S&N say the numbers are the correct interpretation of the guidance it gives a certain validity to the figures. | basildublin | |
12/8/2021 10:18 | Thank you, nothing wrong with doing your own research particularly when you can justify the end result to your own satisfaction. | ianood | |
12/8/2021 08:32 | Ian I am a CA I took the information supplied with H2 Accounts, asked questions of S&N, got prompt replies, finished up with Trading Profits between +37% and +49% over 2020 to which they agreed. Simple ! DYOR | basildublin | |
11/8/2021 23:33 | Basil, thank you. Please what research does that pertain to? | ianood | |
11/8/2021 20:26 | Hold on to your S&N shares. 2021 trading profits are projected to rise between 37% and 49%over 2020 ! | basildublin | |
10/8/2021 22:36 | EI, for what it's worth both ops, 3 years apart, were done under an epidural. I do hold S&N, however, I suspect it may not be for too much longer! | ianood | |
10/8/2021 17:28 | Ian, good to hear of that positive personal experience, surgery under GA is not an option for me so mine better hold out!. The posts not intended to deter anyone from buying here, just for discussion purposes only. Always dyor etc. Phil, lovely price. | essentialinvestor | |
10/8/2021 17:10 | EI, Interesting comment, I have 2 Stryker knees installed via their robotic arm system which guarantees precision of 1mm in limb length and <1 degree deviation in the rotation of the knee from the norm. I did think that SN would be a good base from which Stryker could scale up in UK/Europe but now having seen and felt the product results I am thinking why would they bother, it will gravitate to them by results alone! Also the Stryker system makes component parts comparatively easy to replace and therefore not a complete TKR in the extremely rare event of a failure! | ianood |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions